Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-11
DOI
10.1038/s41598-018-24306-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Dawn Provenzale et al. Journal of the National Comprehensive Cancer Network
- Prognostic impact of mutation profiling in patients with stage II and III colon cancer
- (2016) Yinchen Shen et al. Scientific Reports
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
- (2015) Jing Zhang et al. Scientific Reports
- BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
- (2014) Jing Chen et al. BMC CANCER
- Characterization of rare transformingKRASmutations in sporadic colorectal cancer
- (2014) Joanna HM Tong et al. CANCER BIOLOGY & THERAPY
- Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
- (2014) Marta Schirripa et al. INTERNATIONAL JOURNAL OF CANCER
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- Clinical relevance of KRAS mutations in codon 13: Where are we?
- (2013) Tze-Kiong Er et al. CANCER LETTERS
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
- (2013) Yinchen Shen et al. PLoS One
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
- (2012) Shuji Ogino et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer
- (2011) Xin Wang ONCOLOGY REPORTS
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
- (2010) M. Janakiraman et al. CANCER RESEARCH
- NRAS Mutations Are Rare in Colorectal Cancer
- (2010) Natsumi Irahara et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
- (2009) Y. He et al. CLINICAL CANCER RESEARCH
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now